trending Market Intelligence /marketintelligence/en/news-insights/trending/afC9EAuv-80uFEVrvhr7lw2 content esgSubNav
In This List

AstraZeneca's lung cancer treatment Imfinzi granted priority review by FDA

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022

Blog

Insight Weekly: Reviving nuclear power; 2023 outlook for US financials; PE funds fuel EV sector

Blog

Insight Weekly: Energy reforms after midterms; Crisis ends 'age of gas'; bank deposits fall


AstraZeneca's lung cancer treatment Imfinzi granted priority review by FDA

AstraZeneca PLC and MedImmune's Imfinzi was granted priority review status by the U.S. Food and Drug Administration as it accepted a supplemental biologics license application, or sBLA, for the lung cancer treatment.

The sBLA is based on positive data from the phase 3 Pacific trial of Imfinzi. The study is continuing to evaluate overall survival under the treatment, the trial's other primary endpoint.

Imfinzi or durvalumab, is a monoclonal antibody indicated for treating patients with locally advanced, or Stage 3, unresectable non-small cell lung cancer whose disease has not progressed following platinum-based chemoradiation therapy.

Imfinzi was granted breakthrough therapy designation by the U.S. FDA in July.

MedImmune is AstraZeneca's biologics research and development unit.